Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A regional cohort associated baseline benzodiazepine use with all-cause mortality, an outcome broader than confirmed COVID-related death.
A neurocritical-care cohort showed why treatment timing and selection can change an apparent drug association.
A severe neurodegeneration model retained a measurable response to a GABA-A modulator.
A genetic model showed that altered baseline neurobiology changed one measured response to diazepam.
A laboratory study found that a common TSPO variant did not have the same effect across all tested ligands.
A herbal-medicine interaction experiment used midazolam to investigate metabolic activity.
A translational interaction study found several epidemiological signals but mechanistic support differed across the pairs.
A sequence trial measured procedure time and medication use rather than every dimension of sedation quality.
A clinical review of psychoactive drugs and driving emphasizes the exposure pattern as well as the medicine name.
A prospective cohort identified concomitant medication patterns alongside weight change, without isolating a benzodiazepine mechanism.
A synthesis study traced how related precursors yielded imine-, triazoline-, or aziridine-containing ring systems.
A review discusses peripheral GABA signaling in glucose regulation without establishing benzodiazepines as diabetes treatment.
A rodent study found anticonvulsant effects in some models and no anti-absence effect in another.
A screening study moved from computational candidates to channel testing, while human safety remained unmeasured.
A benzodiazepine-scaffold study reported a selective cytotoxicity signal in vitro, with no patient treatment evidence.
A data paper preserves seizure and behavioral measurements after midazolam-based combination treatment in a nerve-agent model.
A cirrhosis cohort reported benzodiazepines or hypnotics alongside opioids without isolating their contribution to hospital outcomes.
A comparative experiment reported immune changes for two anesthetics that should not automatically be assigned to midazolam.
A St. John’s wort experiment found that extract composition affected a measured diazepam interaction.
A national claims analysis described reduced benzodiazepine use alongside other changes in schizophrenia care, without assigning causation to any single trend.
A secondary analysis tracked both self-reported drug use and urine screens, with important limits on interpreting early changes.
An administrative study of initial depression treatment reported declining benzodiazepine receptor agonist coprescribing, including lorazepam.
A meta-analysis found lower midazolam doses in older patients undergoing endobronchial ultrasound-guided sampling, with broadly comparable procedural outcomes.
A fatal case involving a clonazepam prodrug shows why a negative parent-drug blood result does not necessarily exclude exposure.
A remimazolam-propofol meta-analysis illustrates why a combined safety outcome needs to be unpacked before it is used in a clinical argument.
A large review found diagnosis-dependent associations between psychotropic treatment and suicide-related outcomes, including concerning benzodiazepine signals.
A Quebec cohort describes how benzodiazepines were used alongside other medicines during continuous palliative sedation until death.
A dual-detection chromatography paper used smartphone imaging for higher drug loads and a more sensitive densitometric method for spiked plasma.
A reported recurrence of stress cardiomyopathy after changes in lorazepam use illustrates why the medication timeline matters alongside cardiac findings.
An epilepsy commentary discusses hypersensitivity evidence from different study types, including spontaneous adverse-event reporting.